Fabrication of nanohybrids toward improving therapeutic potential of a NIR photo-sensitizer: An optical spectroscopic and computational study

2021 ◽  
pp. 113610
Author(s):  
Arpan Bera ◽  
Md. Nur Hasan ◽  
Uttam Pal ◽  
Damayanti Bagchi ◽  
Tuhin Kumar Maji ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Computational Study ◽  
Photo Sensitizer

scholarly journals Computational Study of the Therapeutic Potential of Novel Heterocyclic Derivatives against SARS-CoV-2

COVID ◽  
2021 ◽  
Vol 1 (4) ◽  
pp. 757-774
Author(s):  
Benjamin Ayodipupo Babalola ◽  
Tosin Emmanuel Adetobi ◽  
Oluwamayowa Samuel Akinsuyi ◽  
Otunba Ahmed Adebisi ◽  
Elizabeth Oreoluwa Folajimi
Keyword(s):  
Binding Affinity ◽  
Drug Targets ◽  
Therapeutic Potential ◽  
Computational Study ◽  
Docking Simulation ◽  
Therapeutic Interventions ◽  
Binding Motif ◽  
Therapeutic Benefits ◽  
Heterocyclic Derivatives ◽  
Inhibitory Potential

Severe Acute Respiratory Syndrome Coronavirus- 2 (SARS-CoV-2), including the recently reported severe variant B.1.617.2, has been reported to attack the respiratory tract with symptoms that may ultimately lead to death. While studies have been conducted to evaluate therapeutic interventions against the virus, this study evaluated the inhibitory potential of virtually screened novel derivatives and structurally similar compounds towards SARS-CoV-2 via a computational approach. A molecular docking simulation of the inhibitory potentials of the compounds against the SARS-CoV-2 drug targets—main protease (Mpro), spike protein (Spro), and RNA-dependent RNA polymerase (RdRp)—were evaluated and achieved utilizing AutoDock Vina in PyRx workspace. The absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of these compounds were assessed using SwissADME and ADMETLab servers. All the compounds displayed high binding affinities for the SARS-CoV-2 drug targets. However, the C13 exhibited the highest binding affinity for the drug targets, Spro and RdRp, while C15 exhibited the highest binding affinity for Mpro. The compounds interacted with the LEU A:271, LEU A:287, ASP A:289, and LEU A:272 of Mpro and the HIS A:540, PRO A:415, PHE A:486, and LEU A:370 of the Spro receptor binding motif and some active site amino acids of RdRp. The compounds also possess a favourable ADMET profile and showed no tendency towards hERG inhibition, hepatotoxicity, carcinogenicity, mutagenicity, or drug-liver injury. These novel compounds could offer therapeutic benefits against SARS-CoV-2, and wet laboratory experiments are necessary to further validate the results of this computational study.

scholarly journals HPLC/MS Phytochemical Profiling with Antioxidant Activities of Echium humile Desf. Extracts: ADMET Prediction and Computational Study Targeting Human Peroxiredoxin 5 Receptor

Agronomy ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 2165
Author(s):  
Kaïss Aouadi ◽  
Hafedh Hajlaoui ◽  
Soumaya Arraouadi ◽  
Siwar Ghannay ◽  
Mejdi Snoussi ◽  
...  
Keyword(s):  
Ethyl Acetate ◽  
Therapeutic Potential ◽  
Ethyl Acetate Extract ◽  
Antioxidant Activities ◽  
Computational Study ◽  
Condensed Tannin ◽  
Antioxidant Properties ◽  
Binding Potential ◽  
Antioxidant Power ◽  
In Silico Studies

Plant-based antioxidants such as polyphenols have gained significance in primary health care needs, due to their potential and therapeutic use in modern medicine. Thus, the present study aimed to evaluate, for the first time, the effect of solvents on extraction yield, polyphenolics, phytoconstituents and antioxidant properties of various extracts (aqueous, methanol, ethyl acetate, dichloromethane, hexane) of Echium humile Desf. (E. humile Desf.) through in vitro and in silico studies. Statistically, among the various solvents, both methanol (443.05 ± 0.50 mg GAE/g extract) and aqueous (440.59 ± 0.50 mg GAE/g extract) extracts displayed equipotent and highest total phenolics content (TPC), while dichloromethane extract had the maximum total flavonoid content (TFC) (151.69 ± 0.60 mg QE/g extract), total flavonol content (TFlC) (97.39 ± 0.19 mg QE/g extract) and total carotenoids content (TCC) (537.85 ± 5.06 mg β-CE/g). Meanwhile, the highest total condensed tannin content (TCTC) was recorded together with hexane (131.50 ± 0.1 mg GAE/g extract) and dichloromethane (125.74 ± 5.72 GAE/g extract) extracts. The results of antioxidant studies revealed that ethyl acetate extract exhibited a potent scavenging effect through 2,2-diphenyl-1-picrylhydrazyl radical (DPPH•) (IC50 = 17.25 ± 1.76 µg/mL) and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS•+) (1433.30 ± 1.78 µg/mL), while dichloromethane extract displayed significant (p < 0.05) ferric ion reducing antioxidant power (FRAP) activity (375.00 ± 0.02 µg/mL) and total antioxidant capacity (TAC) (1999.00 ± 2.05 µg AAE/g). In addition, the quantification of the polyphenolics content of the most active E. humile Desf. extract, ethyl acetate has been assessed by HPLC/MS, leading to the identification of p-coumaric, trans-ferulic acids and cirsiliol as major constituents. Additionally, molecular docking analysis showed that among the selected phytocompounds, naringin (−7.0 kcal/mol) followed by 1,3-di-O-caffeoyquinic acid (−6.6 kcal/mol), rosmarinic acid (−6.6 kcal/mol), rutin (−6.5 kcal/mol) and apigenin-7-O-glucoside (−6.5 kcal/mol) showed the lowest binding potential. Furthermore, ADME and toxicity parameters justify that identified compounds from ethyl acetate extract are safer to replace the synthetic drugs with side effects. The obtained results can provide valuable information on the medical and therapeutic potential use of E. humile Desf. as a potent antioxidant agent to improve immunity.

Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans

1993 ◽  
Vol 69 (02) ◽  
pp. 157-163 ◽  
Author(s):  
Irving Fox ◽  
Adrian Dawson ◽  
Peter Loynds ◽  
Jane Eisner ◽  
Kathleen Findlen ◽  
...  
Keyword(s):  
Rational Design ◽  
Therapeutic Potential ◽  
Anticoagulant Activity ◽  
Subcutaneous Administration ◽  
Direct Thrombin Inhibitor ◽  
Controlled Study ◽  
Thrombin Inhibitor ◽  
Thrombin Time ◽  
Thrombotic Disease ◽  
Dose Dependent

SummaryHirulog™ (BG8967) is a direct thrombin inhibitor built by rational design using the protein hirudin as a model (Maraganore et al. [1990]; Biochemistry 29: 7095–101). In order to evaluate the therapeutic potential for hirulog in the management of thrombotic disease, the tolerability and anticoagulant activity of the agent were examined in a study of human volunteers.In a randomized, placebo-controlled study (n = 54), the intravenous infusion of hirulog over 15 min showed a rapid, dose-dependent prolongation of activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). There was a corresponding dose-dependent increase in plasma hirulog levels. The peptide was rapidly cleared with a half-life of 36 min and a total body clearance rate for the peptide of 0.43 1 kg−1 h−1. Similar activity was observed following subcutaneous injection but with sustained pharmacodynamic and pharmacokinetic behavior. There was a significant correlation between pharmacokinetic and pharmacodynamic variables for both intravenous (r = 0.8, p <0.001) and subcutaneous administration (r = 0.7, p = 0.002).To evaluate the possible interactions of aspirin on the tolerability and anticoagulant activity of intravenous hirulog, a cross-over design was employed in eight subjects. Aspirin administration did not modify the peptide’s activity. At the administered dose of 0.6 mg kg−1 h−1 for 2 h, hirulog infusion prolonged APTT from 230 to 260% baseline. The infusion of hirulog in subjects who had received aspirin was not associated with any significant changes in the template bleeding time.The final phase of the study examined the activity and tolerability of hirulog in ten subjects during prolonged intravenous infusions for up to 24 h. The peptide (0.3 mg kg−1 h−1) exhibited sustained anticoagulant activity with no evidence for a cumulative effect. During hirulog infusion, APTT was prolonged from 210 to 250% baseline.In all phases of the study, hirulog administration was generally well-tolerated.Our observations show that hirulog is an active antithrombin agent with excellent tolerability in humans. As a direct thrombin inhibitor, hirulog provides a novel approach for the management of thrombotic disease.

Targeting Platelets Containing Electro-encapsulated lloprost to Balloon Injured Aorta in Rats

1995 ◽  
Vol 73 (03) ◽  
pp. 535-542 ◽  
Author(s):  
N Crawford ◽  
A Chajara ◽  
G Pfliegler ◽  
B EI Gamal ◽  
L Brewer ◽  
...  
Keyword(s):  
Time Course ◽  
Therapeutic Potential ◽  
Simple Procedure ◽  
Rat Aorta ◽  
Balloon Injury ◽  
Post Injury ◽  
Antiproliferative Effects ◽  
Platelet Deposition ◽  
Total Dna ◽  
Novel Drug

SummaryDrugs can be electro-encapsulated within platelets and targeted to damaged blood vessels by exploiting the platelet’s natural haemostatic properties to adhere to collagen and other vessel wall constituents revealed by injury. A rat aorta balloon angioplasty model has been used to study the effect on platelet deposition of giving iloprost loaded platelets i.v. during the balloon injury. After labelling the circulating platelets with 111-Indium before balloon injury, time course studies showed maximum platelet deposition on the injured aorta occurred at about 1 h post-injury and the deposition remained stable over the next 2-3 h. When iloprost-loaded platelets were given i.v. during injury and the circulating platelet pool labelled with 111-Indium 30 min later, platelet deposition, measured at 2 h postinjury, was substantially and significantly reduced compared with control platelet treatment. Some antiproliferative effects of iloprost-loaded platelets given i.v. during injury have also been observed. Whereas the incorporation of [3H]-thymidine into aorta intima-media DNA at 3 days post injury was 62-fold higher in balloon injured rats than in control sham operated rats, thymidine incorporation into intima/media of rats which had received iloprost loaded platelets during injury was reduced as compared with rats subjected only to the injury procedure. The reduction was only of near significance, however, but at 14 days after injury the total DNA content of the aorta intima/media of rats given iloprost loaded platelets during injury was significantly reduced. Although iloprost loaded platelets can clearly inhibit excessive platelet deposition, other encapsulated agents may have greater anti-proliferative effects. These studies have shown that drug loaded platelets can be targeted to injured arteries, where they may be retained as depots for local release. We believe this novel drug delivery protocol may have therapeutic potential in reducing the incidence of occlusion and restenosis after angioplasty and thrombolysis treatment. Electro-encapsulation of drugs into platelets is a simple procedure and, using autologous and fully biocompatible and biodegradable platelets as delivery vehicles, might overcome some of the immunological and toxicological problems which have been encountered with other delivery vectors such as liposomes, microbeads, synthetic microcapsules and antibodies.

Sign in / Sign up

Export Citation Format

Share Document